kj1234 personal page - To The Moon

kj1234

kj1234

No personal profile

0Follow

0Followers

0Topic

0Badge

2021-06-28

Good news

Sorry, the original content has been removed

2021-06-28

Woah

Sorry, the original content has been removed

2021-06-18

Good read

Sorry, the original content has been removed

2021-06-16

Good read

Sorry, the original content has been removed

2021-06-16

Good read

China stocks end lower as Sino-West tensions weigh

2021-06-16

Good read

Sorry, the original content has been removed

2021-06-16

Good read

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

2021-06-16

Okay

Blockchain stocks mixed in morning trading

2021-06-15

Need learn more about it

What you need to know to start investing in cryptocurrency right now

2021-06-15

Interesting

JPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026

2021-06-15

Cool

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586863446702582","uuid":"3586863446702582","gmtCreate":1623770104568,"gmtModify":1623815559745,"name":"kj1234","pinyin":"kj1234","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":127601815,"gmtCreate":1624844896837,"gmtModify":1703845989485,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127601815","repostId":"2146007118","repostType":4,"isVote":1,"tweetType":1,"viewCount":2011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127872717,"gmtCreate":1624844673139,"gmtModify":1703845980149,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127872717","repostId":"1136989303","repostType":4,"isVote":1,"tweetType":1,"viewCount":1527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162055071,"gmtCreate":1624028848993,"gmtModify":1703827125129,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162055071","repostId":"1113742137","repostType":4,"isVote":1,"tweetType":1,"viewCount":2069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160376535,"gmtCreate":1623773708727,"gmtModify":1703819108066,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160376535","repostId":"1174890666","repostType":4,"isVote":1,"tweetType":1,"viewCount":1904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160378565,"gmtCreate":1623773688357,"gmtModify":1703819106916,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160378565","repostId":"2143730319","repostType":4,"repost":{"id":"2143730319","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623742806,"share":"https://ttm.financial/m/news/2143730319?lang=en_US&edition=fundamental","pubTime":"2021-06-15 15:40","market":"sh","language":"en","title":"China stocks end lower as Sino-West tensions weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2143730319","media":"Reuters","summary":"SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and t","content":"<p>SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.</p>\n<p>The blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.</p>\n<p>Shares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.</p>\n<p>Among the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.</p>\n<p>Shares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.</p>\n<p>This round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".</p>\n<p>Money inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.</p>\n<p>Investors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.</p>\n<p>($1 = 6.4018 Chinese yuan)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China stocks end lower as Sino-West tensions weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina stocks end lower as Sino-West tensions weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-15 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.</p>\n<p>The blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.</p>\n<p>Shares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.</p>\n<p>Among the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.</p>\n<p>Shares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.</p>\n<p>This round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".</p>\n<p>Money inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.</p>\n<p>Investors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.</p>\n<p>($1 = 6.4018 Chinese yuan)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399001":"深证成指","399006":"创业板指","000001.SH":"上证指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143730319","content_text":"SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.\nThe blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.\nShares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.\nAmong the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.\nShares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.\nThis round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".\nMoney inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.\nInvestors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.\n($1 = 6.4018 Chinese yuan)","news_type":1,"symbols_score_info":{"399001":0.9,"399006":0.9,"000001.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160343800,"gmtCreate":1623773430900,"gmtModify":1703819093968,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160343800","repostId":"1163671123","repostType":4,"isVote":1,"tweetType":1,"viewCount":2652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160349161,"gmtCreate":1623773410953,"gmtModify":1703819088603,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160349161","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://ttm.financial/m/news/1167457915?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160357292,"gmtCreate":1623773382116,"gmtModify":1703819087311,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160357292","repostId":"1180911259","repostType":4,"repost":{"id":"1180911259","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623765092,"share":"https://ttm.financial/m/news/1180911259?lang=en_US&edition=fundamental","pubTime":"2021-06-15 21:51","market":"us","language":"en","title":"Blockchain stocks mixed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1180911259","media":"Tiger Newspress","summary":"(June 15) Blockchain stocks mixed in morning trading.","content":"<p>(June&nbsp;15)&nbsp;Blockchain&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2add04248d60bb69c41121475aca5e34\" tg-width=\"283\" tg-height=\"365\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blockchain stocks mixed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlockchain stocks mixed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June&nbsp;15)&nbsp;Blockchain&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2add04248d60bb69c41121475aca5e34\" tg-width=\"283\" tg-height=\"365\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技","MARA":"MARA Holdings","RIOT":"Riot Platforms","EBON":"亿邦国际"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180911259","content_text":"(June 15) Blockchain stocks mixed in morning trading.","news_type":1,"symbols_score_info":{"CAN":0.9,"EBON":0.9,"RIOT":0.9,"MARA":0.9,"BTBT":0.9}},"isVote":1,"tweetType":1,"viewCount":2500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160942104,"gmtCreate":1623770685408,"gmtModify":1703818959107,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Need learn more about it","listText":"Need learn more about it","text":"Need learn more about it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160942104","repostId":"2143735752","repostType":4,"repost":{"id":"2143735752","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623750480,"share":"https://ttm.financial/m/news/2143735752?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:48","market":"hk","language":"en","title":"What you need to know to start investing in cryptocurrency right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2143735752","media":"Dow Jones","summary":"From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in c","content":"<p>From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.</p>\n<p>MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.</p>\n<p>It's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.</p>\n<p>Cryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.</p>\n<p>While some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.</p>\n<p><b>How to invest in cryptocurrencies</b></p>\n<p>While investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:</p>\n<p>TD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.</p>\n<p>If your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as <a href=\"https://laohu8.com/S/AONE\">one</a> of the following:</p>\n<p><b>Prepare for risk and volatility</b></p>\n<p>Not all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.</p>\n<p>\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .</p>\n<p>Cryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.</p>\n<p>\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p><b>Consider risk-reward dynamics</b></p>\n<p>Investing in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in <a href=\"https://laohu8.com/S/AONE.U\">one</a> asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.</p>\n<p>\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"</p>\n<p>Some investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).</p>\n<p>Finally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p>About the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What you need to know to start investing in cryptocurrency right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat you need to know to start investing in cryptocurrency right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-15 17:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.</p>\n<p>MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.</p>\n<p>It's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.</p>\n<p>Cryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.</p>\n<p>While some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.</p>\n<p><b>How to invest in cryptocurrencies</b></p>\n<p>While investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:</p>\n<p>TD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.</p>\n<p>If your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as <a href=\"https://laohu8.com/S/AONE\">one</a> of the following:</p>\n<p><b>Prepare for risk and volatility</b></p>\n<p>Not all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.</p>\n<p>\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .</p>\n<p>Cryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.</p>\n<p>\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p><b>Consider risk-reward dynamics</b></p>\n<p>Investing in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in <a href=\"https://laohu8.com/S/AONE.U\">one</a> asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.</p>\n<p>\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"</p>\n<p>Some investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).</p>\n<p>Finally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p>About the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","GBTC":"比特币ETF-Grayscale"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143735752","content_text":"From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.\nMarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.\nIt's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.\nCryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.\nWhile some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.\nHow to invest in cryptocurrencies\nWhile investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:\nTD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.\nIf your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as one of the following:\nPrepare for risk and volatility\nNot all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.\n\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .\nCryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.\n\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"\nIf you are ready to invest in crypto, here are a few of your options: Coinbase .\nConsider risk-reward dynamics\nInvesting in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in one asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.\n\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"\nSome investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).\nFinally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"\nIf you are ready to invest in crypto, here are a few of your options: Coinbase .\nAbout the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.","news_type":1,"symbols_score_info":{"COIN":0.9,"GBTC":0.9}},"isVote":1,"tweetType":1,"viewCount":1439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160946877,"gmtCreate":1623770655799,"gmtModify":1703818957791,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160946877","repostId":"1156005756","repostType":4,"repost":{"id":"1156005756","kind":"news","weMediaInfo":{"introduction":"Global Stock News First-Time Broadcast","home_visible":1,"media_name":"Stock News","id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1762157794,"share":"https://ttm.financial/m/news/1156005756?lang=en_US&edition=fundamental","pubTime":"2025-11-03 16:16","market":"fut","language":"en","title":"JPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1156005756","media":"Stock News","summary":"JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a...","content":"<p>JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"80016":"新鸿基地产-R","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BSPPW651.USD":"NEUBERGER BERMAN GLOBAL REAL ESTATE SECURITIES \"A\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1316543674.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A3 SGD","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","BK4534":"瑞士信贷持仓","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4516":"特朗普概念","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU2226123227.USD":"Janus Henderson Horizon Asia-Pacific Property Income A5m USD","BK4207":"综合性银行","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU2226123490.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A5m SGD","LU0229494975.USD":"骏利亨德森亚太地产股票基金","JPM":"摩根大通","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2088747998.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","BK4581":"高盛持仓","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2088748020.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","SG9999010052.SGD":"United Asia Pacific Real Estate Income Dis SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0971096721.USD":"富达环球金融服务 A","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","BK1521":"挪威政府全球养老基金持仓","03121":"华夏亚太房地产","LU0149725797.USD":"汇丰美国股市经济规模基金","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","BK1240":"房地产开发","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2088748376.SGD":"Eastspring Investments - Asia Real Estate Multi Asset Income Cl ASDM SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SG9999010078.USD":"UNITED ASIA PACIFIC REAL ESTATE INCOME (USDHDG) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","BK4550":"红杉资本持仓","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK1559":"蓝筹地产股","BK1216":"多样化房地产活动","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","SUHJY":"新鸿基地产ADR","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","IE00BDRTCR15.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC A","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4585":"ETF&股票定投概念","BK1601":"香港本地股","LU2088748293.HKD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"AHD\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0215105999.USD":"SCHRODER ISF GLOBAL EQUITY \"A\" ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4504":"桥水持仓","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","00083":"信和置业","BK4588":"碎股","IE00B1G9TL16.USD":"FIRST SENTIER ASIAN PROPERTY SECURITIES \"I\" (USD) ACC","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","SG9999009997.SGD":"United Asia Pacific Real Estate Income Acc SGD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4566":"资本集团","LU2088747725.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"A\" (USD) ACC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","00012":"恒基地产","IE00B1G9TM23.USD":"FIRST SENTIER ASIAN PROPERTY SECURITIES \"I\" (USD) INC","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","03145":"华夏亚洲高息股","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","00016":"新鸿基地产"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156005756","content_text":"JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.","news_type":1,"symbols_score_info":{"80016":1,"03121":1,"03145":1,"00012":1,"00016":1,"JPM":1,"00083":1,"SUHJY":1}},"isVote":1,"tweetType":1,"viewCount":2166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160954771,"gmtCreate":1623770464793,"gmtModify":1703818948664,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586863446702582","authorIdStr":"3586863446702582"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160954771","repostId":"1187102856","repostType":4,"isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":127601815,"gmtCreate":1624844896837,"gmtModify":1703845989485,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127601815","repostId":"2146007118","repostType":4,"isVote":1,"tweetType":1,"viewCount":2011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127872717,"gmtCreate":1624844673139,"gmtModify":1703845980149,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127872717","repostId":"1136989303","repostType":4,"isVote":1,"tweetType":1,"viewCount":1527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162055071,"gmtCreate":1624028848993,"gmtModify":1703827125129,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162055071","repostId":"1113742137","repostType":4,"isVote":1,"tweetType":1,"viewCount":2069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160376535,"gmtCreate":1623773708727,"gmtModify":1703819108066,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160376535","repostId":"1174890666","repostType":4,"isVote":1,"tweetType":1,"viewCount":1904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160378565,"gmtCreate":1623773688357,"gmtModify":1703819106916,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160378565","repostId":"2143730319","repostType":4,"repost":{"id":"2143730319","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623742806,"share":"https://ttm.financial/m/news/2143730319?lang=en_US&edition=fundamental","pubTime":"2021-06-15 15:40","market":"sh","language":"en","title":"China stocks end lower as Sino-West tensions weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2143730319","media":"Reuters","summary":"SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and t","content":"<p>SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.</p>\n<p>The blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.</p>\n<p>Shares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.</p>\n<p>Among the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.</p>\n<p>Shares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.</p>\n<p>This round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".</p>\n<p>Money inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.</p>\n<p>Investors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.</p>\n<p>($1 = 6.4018 Chinese yuan)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China stocks end lower as Sino-West tensions weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina stocks end lower as Sino-West tensions weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-15 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.</p>\n<p>The blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.</p>\n<p>Shares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.</p>\n<p>Among the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.</p>\n<p>Shares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.</p>\n<p>This round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".</p>\n<p>Money inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.</p>\n<p>Investors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.</p>\n<p>($1 = 6.4018 Chinese yuan)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399001":"深证成指","399006":"创业板指","000001.SH":"上证指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143730319","content_text":"SHANGHAI, June 15 (Reuters) - China stocks ended lower on Tuesday, as tensions between Beijing and the West soured investor sentiment after G7 leaders took the Asian nation to task over a range of issues, which China called a gross interference in the country's internal affairs.\nThe blue-chip CSI300 index ended 1.1% lower at 5,166.56, while the Shanghai Composite Index slipped 0.9% to 3,556.56.\nShares in China's Belt and Road-related companies dropped, after the G7 leaders sought to counter China's growing influence by offering developing nations an infrastructure plan that could rival President Xi Jinping's multi-trillion-dollar Belt and Road initiative.\nAmong the worst performing sectors, the CSI300 Real Estate Index and the CSI A-share resource industries slumped 2.5% and 2.6%, respectively.\nShares of developers retreated after state media warned speculators that China's housing prices would inevitably enter a cycle of slow growth.\nThis round of real-estate regulations have entered into an in-depth stage and the (market) would be dampened to some extent for the short term, the China Real Estate Business said in an article titled \"It's time for house speculators to give up illusions\".\nMoney inflows from institutional investors had been limited in the past weeks, while foreign inflows via the Stock Connect slowed, CITIC Securities noted in a report.\nInvestors via the Stock Connect linking mainland and Hong Kong sold a net 2.5 billion yuan ($390.52 million) worth of A-shares on Tuesday, according to Refinitiv data.\n($1 = 6.4018 Chinese yuan)","news_type":1,"symbols_score_info":{"399001":0.9,"399006":0.9,"000001.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160343800,"gmtCreate":1623773430900,"gmtModify":1703819093968,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160343800","repostId":"1163671123","repostType":4,"isVote":1,"tweetType":1,"viewCount":2652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160349161,"gmtCreate":1623773410953,"gmtModify":1703819088603,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160349161","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://ttm.financial/m/news/1167457915?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160357292,"gmtCreate":1623773382116,"gmtModify":1703819087311,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160357292","repostId":"1180911259","repostType":4,"repost":{"id":"1180911259","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623765092,"share":"https://ttm.financial/m/news/1180911259?lang=en_US&edition=fundamental","pubTime":"2021-06-15 21:51","market":"us","language":"en","title":"Blockchain stocks mixed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1180911259","media":"Tiger Newspress","summary":"(June 15) Blockchain stocks mixed in morning trading.","content":"<p>(June&nbsp;15)&nbsp;Blockchain&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2add04248d60bb69c41121475aca5e34\" tg-width=\"283\" tg-height=\"365\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blockchain stocks mixed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlockchain stocks mixed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June&nbsp;15)&nbsp;Blockchain&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/2add04248d60bb69c41121475aca5e34\" tg-width=\"283\" tg-height=\"365\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技","MARA":"MARA Holdings","RIOT":"Riot Platforms","EBON":"亿邦国际"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180911259","content_text":"(June 15) Blockchain stocks mixed in morning trading.","news_type":1,"symbols_score_info":{"CAN":0.9,"EBON":0.9,"RIOT":0.9,"MARA":0.9,"BTBT":0.9}},"isVote":1,"tweetType":1,"viewCount":2500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160942104,"gmtCreate":1623770685408,"gmtModify":1703818959107,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Need learn more about it","listText":"Need learn more about it","text":"Need learn more about it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160942104","repostId":"2143735752","repostType":4,"repost":{"id":"2143735752","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623750480,"share":"https://ttm.financial/m/news/2143735752?lang=en_US&edition=fundamental","pubTime":"2021-06-15 17:48","market":"hk","language":"en","title":"What you need to know to start investing in cryptocurrency right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2143735752","media":"Dow Jones","summary":"From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in c","content":"<p>From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.</p>\n<p>MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.</p>\n<p>It's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.</p>\n<p>Cryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.</p>\n<p>While some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.</p>\n<p><b>How to invest in cryptocurrencies</b></p>\n<p>While investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:</p>\n<p>TD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.</p>\n<p>If your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as <a href=\"https://laohu8.com/S/AONE\">one</a> of the following:</p>\n<p><b>Prepare for risk and volatility</b></p>\n<p>Not all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.</p>\n<p>\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .</p>\n<p>Cryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.</p>\n<p>\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p><b>Consider risk-reward dynamics</b></p>\n<p>Investing in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in <a href=\"https://laohu8.com/S/AONE.U\">one</a> asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.</p>\n<p>\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"</p>\n<p>Some investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).</p>\n<p>Finally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p>About the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What you need to know to start investing in cryptocurrency right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat you need to know to start investing in cryptocurrency right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-15 17:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.</p>\n<p>MarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.</p>\n<p>It's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.</p>\n<p>Cryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.</p>\n<p>While some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.</p>\n<p><b>How to invest in cryptocurrencies</b></p>\n<p>While investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:</p>\n<p>TD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.</p>\n<p>If your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as <a href=\"https://laohu8.com/S/AONE\">one</a> of the following:</p>\n<p><b>Prepare for risk and volatility</b></p>\n<p>Not all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.</p>\n<p>\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .</p>\n<p>Cryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.</p>\n<p>\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p><b>Consider risk-reward dynamics</b></p>\n<p>Investing in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in <a href=\"https://laohu8.com/S/AONE.U\">one</a> asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.</p>\n<p>\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"</p>\n<p>Some investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).</p>\n<p>Finally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"</p>\n<p>If you are ready to invest in crypto, here are a few of your options: Coinbase .</p>\n<p>About the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","GBTC":"比特币ETF-Grayscale"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143735752","content_text":"From Robinhood to SoFi Invest, Coinbase to Gemini to eToro, here are some of the ways to invest in crypto -- and advice on whether you should dive in.\nMarketWatch has highlighted these products and services because we think readers will find them useful. We may earn a commission if you buy products through our links, but our recommendations are independent of any compensation that we may receive.\nIt's been a hot year for cryptocurrencies, and 2021 isn't even halfway over. The total value of cryptocurrencies briefly surpassed $2.5 trillion in May as a plethora of new investors jumped in, and now approximately 14% of American adults own cryptocurrencies.\nCryptocurrencies are digital assets that are exchanged online on exchanges like Coinbase . Cryptocurrencies are hardly new. Bitcoin, the first and largest cryptocurrency by market capitalization, was created in 2009 and has been followed by more than 7,700 others. You may have also heard of ethereum, tether, or even dogecoin, which began as a joke and now sits among the 10 largest cryptocurrencies.\nWhile some people are investing purely to speculate, others look at cryptos as a way to store value or hedge against inflation. Here's how to invest in crypto now, whether you should get into it, and what to know before you do.\nHow to invest in cryptocurrencies\nWhile investing in cryptocurrencies has gone mainstream, it's not an option at many traditional online brokers -- yet. Here are a few brokers that allow you to directly hold cryptocurrencies alongside other assets like stocks and bonds, but fees vary and it's key to do your homework:\nTD Ameritrade, Interactive Brokers, and Charles Schwab offer bitcoin futures trading.\nIf your broker doesn't offer cryptocurrencies, you might consider signing up for an account with a crypto exchange, such as one of the following:\nPrepare for risk and volatility\nNot all cryptocurrencies are created alike, and each token has unique characteristics that help dictate its price swings. That's why it's important to learn as much as possible about a specific token before investing, including why it was created (what problem it's trying to solve) and by whom (the governance structure), recommends Chris Kupier, vice president of equity research at CFRA Research.\n\"The more you understand it, the more you're going to approach investing in the 'right' way,\" Kupier says. For example, he likens bitcoin to \"gold 2.0\" because the digital coin has a finite supply and is seen by some as a way to store value and hedge against inflation -- characteristics that don't apply to ethereum, for example. (Note that this bitcoin-is-the-new-gold take is certainly not shared by everyone, as this MarketWatch .\nCryptocurrencies fall under the umbrella of alternative assets (like commodities or real estate) because they offer a way to diversify your portfolio and have a low correlation to other assets, like stocks and bonds, Kupier notes. But cryptocurrencies are volatile, and because trading occurs 24/7, 365 days a year, that allows traders to react immediately to news -- or even tweets . Indeed, this year, tweets from Elon Musk, CEO of Tesla, caused crypto prices to both jump and slump.\n\"Look, this is the Wild West, so you have to be ready for it,\" Kupier says. While bitcoin has experienced average annualized returns in excess of 200%, that's come with huge price slumps, he adds. \"You need to embrace the volatility if you want those gains.\"\nIf you are ready to invest in crypto, here are a few of your options: Coinbase .\nConsider risk-reward dynamics\nInvesting in crypto is not for everyone. Those who do dive in should remember this: Given the extreme volatility, moderation is key, notes Matt Schwartz, senior advisor and a certified financial planner with Great Waters Financial. Just as you shouldn't invest all of your money in one asset -- like a stock or bond -- cryptocurrencies should have a limited impact on the risk-reward dynamics of your overall portfolio, he adds.\n\"If you have 2%-5% of your portfolio allocated to any asset class, that isn't going to move the needle on your overall portfolio that much,\" Schwartz says, adding that the exact allocation is unique to each investor. \"It's important to think about your own situation and how it may or may not help you accomplish your goals.\"\nSome investing pros say that if you do want to dive into crypto, a smart way to do it may be through dollar-cost averaging, which simply means investing a fixed amount at regular intervals. And be sure to consult an accountant about the tax implications of trading (it can get pricey).\nFinally, be mindful of how investment decisions affect you. \"Don't take on so much risk that you can't sleep at night,\" Kupier says. \"But the opposite is true: If you're constantly watching bitcoin because you have 0% invested and you're watching it go up, you probably need to buy a little of it for peace of mind.\"\nIf you are ready to invest in crypto, here are a few of your options: Coinbase .\nAbout the author: Anna-Louise Jackson is a financial journalist with more than a decade of writing and editing experience. She was a reporter for Bloomberg News, covering the U.S. economy, U.S. stock market, and corporate finance. Her work has also appeared in/on NerdWallet, CNBC, The Associated Press, USA Today, Forbes, Fortune, and Money.","news_type":1,"symbols_score_info":{"COIN":0.9,"GBTC":0.9}},"isVote":1,"tweetType":1,"viewCount":1439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160946877,"gmtCreate":1623770655799,"gmtModify":1703818957791,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160946877","repostId":"1156005756","repostType":4,"repost":{"id":"1156005756","kind":"news","weMediaInfo":{"introduction":"Global Stock News First-Time Broadcast","home_visible":1,"media_name":"Stock News","id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1762157794,"share":"https://ttm.financial/m/news/1156005756?lang=en_US&edition=fundamental","pubTime":"2025-11-03 16:16","market":"fut","language":"en","title":"JPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1156005756","media":"Stock News","summary":"JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a...","content":"<p>JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan: More Signs Point to Sustained Recovery in Residential Market, Predicts Further 5% Price Rebound by End-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"80016":"新鸿基地产-R","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BSPPW651.USD":"NEUBERGER BERMAN GLOBAL REAL ESTATE SECURITIES \"A\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1316543674.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A3 SGD","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","BK4534":"瑞士信贷持仓","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4516":"特朗普概念","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU2226123227.USD":"Janus Henderson Horizon Asia-Pacific Property Income A5m USD","BK4207":"综合性银行","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU2226123490.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A5m SGD","LU0229494975.USD":"骏利亨德森亚太地产股票基金","JPM":"摩根大通","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2088747998.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","BK4581":"高盛持仓","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2088748020.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","SG9999010052.SGD":"United Asia Pacific Real Estate Income Dis SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0971096721.USD":"富达环球金融服务 A","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","BK1521":"挪威政府全球养老基金持仓","03121":"华夏亚太房地产","LU0149725797.USD":"汇丰美国股市经济规模基金","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","BK1240":"房地产开发","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2088748376.SGD":"Eastspring Investments - Asia Real Estate Multi Asset Income Cl ASDM SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SG9999010078.USD":"UNITED ASIA PACIFIC REAL ESTATE INCOME (USDHDG) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","BK4550":"红杉资本持仓","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK1559":"蓝筹地产股","BK1216":"多样化房地产活动","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","SUHJY":"新鸿基地产ADR","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","IE00BDRTCR15.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC A","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4585":"ETF&股票定投概念","BK1601":"香港本地股","LU2088748293.HKD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"AHD\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0215105999.USD":"SCHRODER ISF GLOBAL EQUITY \"A\" ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4504":"桥水持仓","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","00083":"信和置业","BK4588":"碎股","IE00B1G9TL16.USD":"FIRST SENTIER ASIAN PROPERTY SECURITIES \"I\" (USD) ACC","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","SG9999009997.SGD":"United Asia Pacific Real Estate Income Acc SGD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4566":"资本集团","LU2088747725.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"A\" (USD) ACC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","00012":"恒基地产","IE00B1G9TM23.USD":"FIRST SENTIER ASIAN PROPERTY SECURITIES \"I\" (USD) INC","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","03145":"华夏亚洲高息股","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","00016":"新鸿基地产"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156005756","content_text":"JPMorgan has released a research report stating that Hong Kong residential property prices have rebounded over 4% since their March 2025 trough. The bank observes increasing signs supporting a sustained recovery in the housing market, including resilient stock market performance (historically showing strong correlation with property prices via wealth effects), pent-up demand driving consistently strong transaction volumes, banks raising property valuations, declining listing volumes in the secondary market, more transactions closing above valuation prices (fueling FOMO sentiment), expectations of further (at least modest) mortgage rate cuts, shrinking inventory levels, rising rents, sustained interest from mainland buyers (whose population is projected for structural growth), and financial sector recovery (Hong Kong's largest GDP contributor). Against this backdrop, the bank forecasts an additional ~5% price rebound by end-2026. While acknowledging persistent headwinds (e.g., potential price cuts by high-risk developers, elevated unemployment in certain sectors), JPMorgan believes positive factors will dominate near-term dynamics. However, its constructive outlook hinges on continued Hang Seng Index resilience, given the sentiment-driven nature of property markets - with a key downside risk being stock market crashes (though not the base case). Among Hong Kong developers, JPMorgan prefers SINO LAND (00083) (lower risk; secure 6% dividend yield), followed by HENDERSON LAND (00012) (higher 6.6% yield but with dividend cut risks). The bank would consider buying SHK PPT (00016) if shares retreat to ~HK$85.","news_type":1,"symbols_score_info":{"80016":1,"03121":1,"03145":1,"00012":1,"00016":1,"JPM":1,"00083":1,"SUHJY":1}},"isVote":1,"tweetType":1,"viewCount":2166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160954771,"gmtCreate":1623770464793,"gmtModify":1703818948664,"author":{"id":"3586863446702582","authorId":"3586863446702582","name":"kj1234","avatar":"https://static.tigerbbs.com/d429c1d423b4f758c14e073337450edc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586863446702582","idStr":"3586863446702582"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160954771","repostId":"1187102856","repostType":4,"isVote":1,"tweetType":1,"viewCount":649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}